Shots:
- Pfizer has discontinued the development of danuglipron (PF-06882961) as a potential therapy for chronic weight management
- Danuglipron was evaluated in 2 P-I trials (NCT06567327 & NCT06568731), meeting key PK objectives & confirming formulation & dose with potential for strong efficacy & tolerability in P-III. However, a case of drug-induced liver injury & recent regulatory input led to discontinuation of the development program
- Danuglipron’s (GLP-1 receptor agonist) clinical data will be presented at a future conference & published in a peer-reviewed journal
Ref: Pfizer | Image: Pfizer
Related News:- Pfizer Secures the EC’s Approval for Abrysvo (Respiratory Syncytial Virus Vaccine) for RSV Lower Respiratory Tract Disease
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Fitness trackers
Click here to read the full press release
